Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,717.00-0.11%ETH$2,283.62+1.03%GOLD$3,910.80+0.31%OIL$99.52-4.42%
Smart Investors Daily
SID Premium
ZN

NASDAQ · ZNTL

Zentalis Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.96

Down-$0.03 (-1.51%)

Updated Nov 2, 2026, 11:47 AM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
104.4M
P/E ratio
-0.64
Dividend yield
0.00%
52-week range
$1.21 – $6.95
Volume
1.33M
Avg. volume
673.52K

Price performance · ZNTL

ZNTL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ZNTL closed at $1.96 after 20 trading sessions, down 29.50% for the selected period.

Last close
$1.96
Period change
-29.50%
Period low
$1.96
Period high
$2.78
Daily close
View OHLC price history
ZNTL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.99$1.99$1.86$1.961.33M
Oct 29, 2026$2.06$2.11$1.97$1.991.45M
Oct 28, 2026$1.99$2.095$1.98$2.062.2M
Oct 27, 2026$2.07$2.118$1.96$1.981.72M
Oct 26, 2026$2.21$2.27$2.03$2.071.06M
Oct 23, 2026$2.41$2.41$2.18$2.21947.07K
Oct 22, 2026$2.33$2.43$2.29$2.41746.23K
Oct 21, 2026$2.36$2.47$2.34$2.361.21M
Oct 20, 2026$2.31$2.4399$2.25$2.391.56M
Oct 19, 2026$2.33$2.3557$2.07$2.302.74M
Oct 16, 2026$2.25$2.30$2.10$2.131.1M
Oct 15, 2026$2.27$2.3963$2.21$2.242.03M
Oct 14, 2026$2.44$2.45$2.30$2.32865.65K
Oct 13, 2026$2.53$2.54$2.39$2.40570.1K
Oct 12, 2026$2.64$2.64$2.51$2.52546.55K
Oct 9, 2026$2.56$2.6589$2.5112$2.64612.37K
Oct 8, 2026$2.51$2.535$2.39$2.511.27M
Oct 7, 2026$2.63$2.68$2.54$2.55820.08K
Oct 6, 2026$2.81$2.8199$2.65$2.67827.9K
Oct 5, 2026$2.69$2.8399$2.63$2.782.99M

Latest ZNTL news

The latest Smart Investors Daily articles mentioning ZNTL.

Stock researchCompany · Overview

ZNTL research

Overview

Company profile and research snapshot.

Company profile

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
ZNTL recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Sep 16, 2026William BlairOutperform—
Jul 23, 2026Rodman & RenshawBuy—
Jul 17, 2026MizuhoOutperform—
Apr 10, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reportingMedian relative dose intensity was 84.6%, confirming high overall exposure to azenosertibDENALI Part 1b interim analysis adds to the body of evidence supporting Cyclin E1 protein expression as a predictive biomarker for azenosertib in platinum-resistant ovarian cancer SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmace

Yahoo · Oct 18, 2026

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026 SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovari

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By